The MS Trust is very disappointed that NICE is unable to recommend ocrelizumab as an NHS treatment for early primary progressive MS.
NICE has approved ocrelizumab (Ocrevus) as a treatment for relapsing remitting multiple sclerosis on the NHS in England and Wales.
- NICE say yes to Ocrevus for RRMS
- Review of medical cannabis
- PIP review changes
- Tysabri in SPMS
- Stress linked to MS risk
On September 5, 2017, the MS Trust announced that it would be working with NHS Lanarkshire to improve access to MS nurses in the area, and ensure people living with MS get the support they need. Nine months on, we're pleased to report on the positive difference the new MS nurses have made to people with MS in Lanarkshire.
- School project explores MS
- Tecfidera and Gilenya compared
- Ocrevus delays progression
- Ocrevus in PPMS - new trial announced
- Obesity and smoking and risk of MS
- Family support helps
- NICE approves injectable drugs for relapsing MS
- Gilenya approved for young Americans
- AAN meeting round up
- RCN supports medical cannabis
- Vitamins and dietary supplements
We'd like to wish the best of luck to longstanding MS Trust supporter Jim Thompson as he begins a 1,300 mile trek.
NICE approves Avonex, Extavia and Rebif, Copaxone and Brabio, does not recommend Betaferon and will assess Plegridy separately.